


Remarks

Pursuant to the Examiner's three-way restriction requirement of March 31, 2003, Applicants elect Group I which is directed to compounds and compositions of Formula (I). Additionally, Applicants were required to elect a single disclosed species. Applicants herein elect (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane which is Example 5 on page 39 of the specification.



(1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane

Accordingly, the claims for the instant application have been amended to reflect the elected subject matter. Claims 1-3, 6, 7, 9, 11, 13, 14, 16, 17, 19, 21, 22, 27-30 and 40-42 are among those that read on the elected species and remain in consideration. Pursuant to MPEP 809.04 and Examiner's notice regarding rejoinder of claims, Applicants reserve the right to reintroduce method of use and process claims which include all the limitations of any elected composition claims (linking claims) that are deemed to be allowable. Applicants also reserve the right to file divisional application(s) on non-elected subject matter.

The undersigned regrets not receiving the Examiner's telephone call of March 20, 2003 and invites the Examiner to telephone for any matter in the future.

Applicants respectfully submit that the application is in condition for examination according to the Examiner's restriction requirement. The Commissioner is authorized to withdraw any fees from Deposit Account 19-3880.

Dated: April 28, 2003

Bristol-Myers Squibb Company
5 Research Parkway, P.O. Box 5100
Wallingford, CT 06492-7660
Phone: (203) 677-7268
Facsimile: (203) 677-6900

Respectfully submitted,

Shah R. Makujina
Attorney for Applicant
Registration No. 41,174